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Progressive multiple sclerosis (MS) is characterized clinically by the accumulation of neurological disability without
unequivocal recovery. Understanding the mechanisms that determine entering in this stage of the disease is a
great challenge in order to identify potential therapeutic targets. Recent advances in defining more accurately the
progressive phenotype of MS, have concluded that differences between primary and secondary progressive forms
of disease are relatively quantitative rather than qualitative. In both cases, a large number of molecular and cellular
events that might lead to neurodegeneration have been suggested. These include microglia activation, chronic
oxidative injury, accumulation of mitochondrial damage in axons, age-related disturbances and dysfunctional axonal
transport among others. Commonly, these pathological mechanisms have been considered as a result of
inflammatory demyelination but a primary degenerative condition has also been argued. It is now clear that both
events contribute to the progression of the disease, however their temporal sequence is still a matter of debate. A
detailed knowledge of progressive MS pathogenesis will allow to develop effective treatments for both progression
and symptom management that should be based on a combination of anti-inflammatory, regenerative and
neuroprotective strategies. In this review, we summarize current data and recent hypothesis about pathological
forces that drive progression of damage in MS, i.e. cumulative cortical demyelination and neurodegeneration as
well as diffuse alterations (microglia activation, axonal injury and atrophy) throughout white and grey matter in the
brain and spinal cord. Finally, we discuss the potential of the aforementioned proposed disease mechanisms with
regard to developing suitable therapies to halt the progression in MS pathology.
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Multiple sclerosis (MS) is a chronic inflammatory, de-
myelinating and neurodegenerative disorder of the cen-
tral nervous system (CNS) and it is the most common
cause of non-traumatic neurological disability in young
adults [1–7]. The diagnostic criteria for MS are the clinical
course of disease supported by paraclinical laboratory as-
sessments and the demonstration by magnetic resonance
imaging (MRI) of dissemination of lesions in space and
time. The initial clinical phenotype of MS is frequently
characterized by episodes of neurological disturbances
followed with residual deficits or full recovery (relapsing-
remitting MS, RRMS) and in a minority (10–20 %) by a* Correspondence: fernando.perez@ehu.eus
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progressive MS, PPMS). Usually with time, a majority of
RRMS patients (up to 70 %) transitions into a predomin-
ant gradual worsening over exacerbations or relapses (sec-
ondary progressive MS, SPMS) [8].
Recently, the classification of the MS phenotypes has
been reorganized into categories according to the presence/
absence of activity and/or gradual illness progression [9].
Disease activity is defined by clinical relapses and/or lesion
activity in CNS imaging and is related to episodes of tissue
injury associated with inflammation. Progression is linked
to increasing neurologic dysfunction which by current
understanding reflects neurodegenerative processes.
Progression and activity are very close to one another
but conceptually four phenotypes are possible: progression
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Table 1 Key aspects of progressive multiple sclerosis (PMS)
distinguishing it from relapsing-remitting multiple sclerosis
(RRMS)
- Time to disability progression is not driven by relapse rate, frequency
or severity
- Fewer active plaques (less inflammation and peripheral immune cell
activation and fewer gadolinium enhancing lesions [signifying fewer
blood-brain barrier breaches])
- Compartmentalised inflammation within the central nervous system
(CNS): meningeal inflammatory aggregates (lymphatic follicles-like)
- More neurodegeneration: more demyelination and axonal loss in
gray matter; more cortical pathology (subpial lesions are almost
specific of PMS) and CNS atrophy
- More diffuse abnormalities and tissue loss in the normal appearing CNS
- Universal progressive spinal cord disease
- Anti-inflammatory therapies less effective or ineffective
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SPMS and PPMS are considered parts of the spectrum of
progressive MS (PMS) phenotypes and differences be-
tween them are relative rather than absolute. Almost no
treatment options are available for PMS patients (more
than 50 % of people with MS), so a good clinical classifica-
tion of patients is very important to better design trials for
study the value of new therapies [10, 11]. However, the
most fundamental issue in developing new treatments for
PMS is to understand the pathological events that under-
pin the disease process.
The pathological mechanisms that drive neurodegen-
eration in PMS are poorly understood though a large
range of disease processes have been proposed as dis-
cussed here. Commonly, neurodegeneration has been
regarded as a result of inflammatory demyelination due
to peripheral immune system activation (the outside-in
hypothesis). Recently an explanation of disease progres-
sion suggests that inflammatory demyelinating processes
in early MS trigger a cascade of events (among others
microglia activation, chronic oxidative injury, mitochon-
drial damage in axons) that lead to neurodegeneration
and are amplified by pathogenic mechanisms related to
brain ageing and accumulated disease burden [2, 12–14].
Alternatively, MS can be regarded as a primary degen-
erative condition which initiates in the myelinating unit
(oligodendroglia, their processes and myelin) and results
in neuroinflammation (the inside-out hypothesis) [15, 16].
It is highly likely that immune-triggered inflammation in
turn drives further damage and degeneration of CNS ele-
ments, creating a vicious circle. According to this hypoth-
esis, progression in MS would be present from the
beginning of illness and progressive cytodegeneration
would underlie all disease processes. Resolution of these
conflicting ideas is unresolved, nonetheless both suggest
that treatment of PMS, preferable at the early stages of
disease, should be based on a combination of anti-
inflammatory, regenerative and neuroprotective strategies
[11, 17, 18]. Nevertheless, although inflammatory and
neurodegenerative events act in concert to induce MS-
specific brain damage their relevance changes during the
course of chronic disease evolution.
Review
The pathology of MS is defined by a spectrum of tissue
alterations in the CNS [2, 6, 19]. Classically include pla-
ques of primary demyelination with oligodendrocyte loss
and profound axonal degeneration surrounded by an
astrocytic scar formation in the white and gray matter of
the brain and spinal cord. These plaques are typically in-
active and very frequent in all stages of MS. In contrast,
active lesions display a focal disruption of the blood-
brain-barrier (BBB) together with inflammatory cells
(lymphocytes, macrophages and activated microglia)which are present throughout the lesion or at the periph-
ery in acute or chronic active plaques respectively. In PMS
half of focal plaques are characterized by a peripheral
small rim composed of a small number of inflammatory
cells (slowly expanding pre-existing lesions) whereas dam-
age to BBB is less obvious. In addition to focal plaques,
diffuse alterations affecting the normal-appearing CNS
with a low-grade on-going inflammation are seen in pa-
tients with PMS (Table 1). These changes include micro-
glial activation mild demyelination and axonal-neuronal
loss in the context of an inflammatory process partly com-
partmentalized behind an intact BBB.
There is an increasing recognition in the MS field
[6, 12, 14, 19–22] that progression of disease that finally
result in CNS atrophy, is related with the accumulation
over time of the following lesions:
– grey matter demyelination, particularly with a
subpial location, largely irrespective of immune cell
infiltration and lesion load in white matter tracts;
and that is associated with both a very limited
remyelination capacity and destruction and loss of
nerve cells.
– diffuse tissue loss in the normal-appearing CNS, that
are only weakly correlated with the number, size and
destructive changes in classical focal white matter
lesions.
Assuming that SPMS and PPMS share the same
pathologic basis implies that in SPMS patients neurode-
generation occurs from the beginning of disease, even
before symptoms of relapses (clinically active inflamma-
tion) appear. Likewise, there will be an ongoing chronic
“below the radar” subclinical inflammation in PPMS pa-
tients, prior to onset of progressive neurodegenerative
symptoms. Accordingly, it has been recently proposed
that a cascade of immunological and neurodegenerative
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[12]. Key elements driving neurodegeneration include
microglia activation, chronic oxidative injury, accumulation
of mitochondrial damage in axons, and age-related iron
accumulation in the human CNS [5, 13, 14, 21, 23, 24].
Altered mitochondrial damage in axons might be of par-
ticular importance since it leads to chronic cell stress and
imbalance of ionic homeostasis, resulting in axonal and
neuronal death.
Loss of the symbiotic relationship between the axon
and myelin sheath after persistent demyelination in MS
causes progressive axonal damage providing a logical ex-
planation for continuous and irreversible neurological
decline in PMS. Chronic deprivation of myelin-derived
trophic support of axons, results in a slowly development
of axonopathy manifested by axonal swelling, reduction in
axonal calibre and ultimately axonal degeneration. Current
hypotheses indicate that the compensatory plasticity of
the CNS delays the onset and progression of neurological
decline in MS patients. Adaptative and neuroprotective
mechanisms that may compensate for initial dysfunction
include activation of cortical areas, neurogenesis, remyeli-
nation, redistribution of sodium channels on demyelinated
axons, increases in mitochondrial content and respiratory
functions in axons and enhanced production of neuro-
trophic factors by CNS resident cells [22, 25]. However,
once a threshold of axonal loss is reached the exhaustion
of the functional reservoir results in a steady progression
of MS.
Neuropathological features of progressive
multiple sclerosis
How do chronically demyelinated axons and neurons de-
generate? It has been suggested that failure of remyelina-
tion is the pathological substrate for disease progression
in MS [1, 26]. In fact, the pattern of tissue injury in PMS
is quite homogeneous and it is characterized by oligo-
dendrocyte loss, demyelination and lack of remyelination,
as well as preferential destruction of small-calibre axons
and astrocytic gliosis. Characteristics of PMS pathology
are focal lesions of demyelination, strips or bands of cor-
tical demyelination and diffuse pathology in the normal
appearing white and grey matter (Table 1).
– An absence of focal new inflammatory
demyelinating lesions as measured by MRI and
histopathology is predominant in the course of PMS
[2]. Inactive or slowly spanding pre-existing MS
plaques are usually seen, latter characterized by a
rim of microglia and a low-grade myelin and axonal
destruction at the lesion edge. But “inactivity” does
not mean stability of disease lesions. Most axons can
survive acute demyelination, and some grade of
remyelination is possible if active lesions areresolved, but chronically demyelinated axons
degenerate. Dynamics of axonal loss are not well
documented but this is a prominent feature of PMS
that can explain partly the concomitant CNS atrophy
observed and is the major cause of irreversible
neurological disability.
– Cortical and deep grey matter demyelination is very
common in MS and exceeds white matter
demyelination. However, little is known about its
dynamics because lesion load measures have been
difficult both by MRI and by histopathology
[26–28]. In PMS strips or bands of subpial cortical
demyelination, which differ in appearance from
intracortical and leukocortical focal lesions ones, are
by far the biggest contributors to total cortical lesion
load, and do not occur in other inflammatory or
non-inflammatory human CNS diseases. In addition
to demyelination and oligodendrocyte loss, cortical
lesions show neuritic transections, neuronal death
and synaptic loss and when active are linked to local
inflammation in the meninges and activation of
microglia. Similar alterations also occur in spinal
cord and other CNS locations of grey matter.
– On the other hand, macroscopically normal
appearing CNS of patients with MS also show
diffuse and global changes that are already present
from the beginning of disease [19, 21]. They include
microglial activation, astrocytic gliosis and mild
inflammation, demyelination, and axonal injury.
With time there is an increasing and progressive
loss of axons in the normal-appearing white matter
and of neurons in gray matter which correlates with
the CNS atrophy that appear in advanced PMS. This
atrophy does not correlate with focal lesions load
suggesting that diffuse neurodegeneration is at least
partly, an independent process from anterograde
Wallerian degeneration and/or retrograde neuronal
dying back started in white and gray plaques.
Molecular mechanisms underlying progression in
multiple sclerosis
They are summarized in Table 2 and detailed in the
following subsections.
Inflammation and microglial activation
In all forms of MS, inflammation is always present when
active demyelination and neurodegeneration occur
[3, 12, 20]. Inflammatory released products as reactive
oxygen or nitric oxide species (ROS and RNS), excito-
toxins as glutamate, and cytotoxic cytokines alter mye-
lin sheaths and cellular metabolism in neurons and
their axons. However inflammation declines with dis-
ease duration while neurodegeneration proceeds and
activated microglia persists in all lesions in PMS [29].
Table 2 Mechanisms and amplification factors for
neurodegeneration in progressive multiple sclerosis (PMS)
- Chronic microglial activation and low-grade inflammation: excitotoxicity,
and chronic oxidative stress which leads to mitochondrial injury
- Mitochondrial dysfunction (energy failure; ionic imbalance) that
might underlie features of Multiple Sclerosis lesions: demyelination,
oligodendrocyte apoptosis and lack of remyelination; and axonal
injury
- Accumulation of lesion burden: retrograde and anterograde
degeneration of demyelinated axons due to lack of trophic support
and abnormal axonal excitability (altered expression of ion
channels) and amplification of microglia activation
- Mitochondrial DNA deletion over time and with age as in other
classical neurodegenerative diseases: increased energy deficiency
and amplification of oxidative injury
- Iron accumulation with ageing in the brain cells and release of iron
in demyelinating lesions (more oxidative injury)
- Progression of age-related neurodegeneration and exhaustion of
central nervous system functional reserve capacity
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disease, is a cause (the outside-in theory: immune dysreg-
ulation) or result of neurodegeneration (inside-out model:
governed by released immunogenic material after cytode-
generation) remains to be determined [15]. Also, a key un-
resolved question is if the inflammatory response is
qualitatively the same in PMS as in other stages of disease
where different patterns of inflammatory processes occur
[30, 31]. Quantitatively, PMS inflammation becomes, at
least in part, trapped within the CNS behind an unaffected
BBB forming lymph follicle-like aggregates in the menin-
ges. Demyelination and neurodegeneration in the cortex
of PMS patients are more pronounced when these struc-
tures are present [32].
Microglial activation, probably due to a chronically in-
flammatory milieu, is invariably seen in the CNS of pa-
tients with PMS [33]. However this is common in many
other CNS diseases in absence of selective primary demye-
lination. Perhaps the “specific” contribution of chronically
activated microglia to the induction of demyelination and
progressive axonal injury in MS is the generation of
chronic oxidative stress, by xanthine and NADPH (nico-
tinamide-adenine dinucleotide phosphate) oxidases as
well as myeloperoxidase, and subsequent mitochondrial
injury in axons and oligodendrocytes. In addition, acti-
vated microglia impairs glutamate transport in astro-
cytes, and thus, promote neuronal and oligodendrocyte
excitotoxicity [5, 12, 33].
Mitochondrial injury and axonal energy failure
Several lines of evidence have led to the hypothesis that
mitochondrial injury is a primary phenomenon in MS
[24, 34]. Remarkably, mitochondria and mitochondrial
DNA, essential for oxidative phosphorylation, are highly
susceptible to oxidative injury. In fact, chronic increasedlocal levels of ROS and RNS by activated microglia are
pronounced in PMS despite low levels of inflammation
and can promote mitochondrial dysfunction. Moreover,
the mechanisms of axonal degeneration in MS are simi-
lar to those occurring in ischemic/hypoxic insults. Thus,
it has been hypothesized that energy deficiency or “vir-
tual hypoxia” might have also a pathogenic role in MS.
Demyelination has a substantial effect on axonal mito-
chondria and renders the demyelinated axon susceptible
to chronic environmental conditions that eventually re-
sult in axon transection and degeneration. Key features
related to mitochondrial dysfunction [2, 5, 12, 13, 19, 22, 34]
are the following:
– After demyelination, aberrant expression of Na+
channels along the entire length of the demyelinated
axon increases energy demands of nerve conduction,
and ATP production by mitochondria might become
compromised causing axoplasmic ionic imbalance
and intracellular Ca2+ accumulation. In conditions of
energy deficiency and mitochondrial “functional
overload”, the ATP-dependent Na+ pump does not
remove Na+, which accumulates in the axon an is
replaced by Ca2+ through reverse operation of the
Na+/Ca2+ exchanger. Additional Ca2+ enters the
axon via glutamate receptors and voltage-gated Ca2+
channels present in the axolemma. If mitochondrial
damage passes a certain threshold, reduced local
energy production might precipitate axonal
demise. In that way, thin-calibre axons with
proportionally less mitochondria in relation to the
surface area of axolemma than thick ones, are
more severely affected.
– When axoplasmic Ca2+ accumulation exceeds the
buffering capacity by mitochondria, initiates a
vicious cycle of deleterious and finally fatal effects
on the axon characterized by activation of
degradative enzymes that compromise axonal
transport, impaired mitochondrial operation,
reduced energy production, and more axoplasmic
Ca2+. In fact, cytoskeletal disturbances as
fragmentation of neurofilaments by Ca2+ activated
degradative enzymes as calpain, appear in chronic
MS lesions, altering the turnover and redistribution
of mitochondria and fast axonal transport. Also, in
patients with PMS, a lost or impaired functional
activity of mitochondrial respiratory chain
complexes has been described in neurons.
Therefore, chronic mitochondrial injury amplifies
chronic oxidative stress present in MS and viceversa.
Additionally, oxidative injury causes mitochondrial
DNA deletions in both the white matter and grey
matter. Accumulation of mitochondrial dysfunctions
in patients with PMS as a final result of the
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susceptibility of brain tissue to neurodegeneration
through enhancement of oxidative injury, energy
failure and altered calcium homeostasis.
– In oligodendrocytes, mitochondrial injury results in the
release of apoptosis-inducing factor, its translocation
into the nucleus and induction of DNA damage
which ultimately leads to cell death.
Age-dependent iron accumulation amplifies injury
in PMS
Iron accumulation in patients with MS can further amp-
lify ROS and RNS mediated injury, by generating toxic
reactants [2, 5, 12]. Iron loading in the brain increases
with age and is predominantly stored in oligodendro-
cytes in the non-toxic ferric (Fe3+) form bound to fer-
ritin. Importantly, injury of these cells during MS
releases iron into the extracellular space where it is con-
verted into Fe2+, which might further amplify oxidative
damage in axons and other cells. Released iron is then
taken up by activated microglia, which becomes dys-
trophic and degenerate, releasing a second way of Fe2+
and increasing the susceptibility of the surrounding
tissue to free-radical-driven demyelination and neurode-
generation. It is worth noting that although iron accu-
mulation is an age-dependent process, and for that
reason likely more pronounced in PMS than previously
in the disease, the pathogenic role of iron in MS is on
discussion. In fact, in chronic MS, a significant decrease
in iron levels is observed in normal appearing CNS [35].
Also it must be taken into account that previous disease
history also influences the development of neurodegenera-
tive amplification damage. In fact, the earlier and/or higher
relapse rates, the shorter time to onset of PMS [9].
Advances in imaging in progressive multiple
sclerosis
Pathological assessment is the gold standard to identify
MS lesions, but there are intrinsic limitations due to the
very limited availability of biopsy tissue and additionally,
tissue evaluation only provides one snapshot in time, not
allowing observation of the evolution of pathological
changes over time. Because of that, MRI and related
techniques with higher specificity are promising tools
for a better understanding of the pathophysiology of the
PMS “in vivo” [8]. Although conventional T1-weighted
images show less sensitivity than T2-weighted MRI im-
ages, they are more specific to MS pathology and prob-
ably T1 hypointense signals are reflecting tissue lesions
with oedema, demyelination, neuroaxonal loss and glio-
sis [36]. In clinical practice, it is difficult to differentiate
a case of PMS from RRMS using MRI [8, 37–39], but
studies have found some population-based differences
between these two groups. In PMS, there is somehow apreponderance of spinal cord/brainstem lesions and rela-
tive paucity of new gadolinium-enhancing brain lesions
over time. A decrease in their occurrence is related to the
clinical transition from RRMS to SPMS. Also there are dif-
ferences in brain atrophy localization, mainly due to loss of
white matter in RRMS as seen by ventricular enlargement,
while in PMS atrophy tends to be more a cortical
phenomenon, particularly common in PPMS. However
conventional MRI approaches are basically unable to detect
cortical lesions and diffuse tissue damage in the normal
appearing CNS. As a consequence, they correlate only
weakly with clinical manifestations and evolution of PMS.
On the contrary, advanced MRI techniques that are
far away of being integrated into routine clinical practice
at present, have shown greater sensitivity and specificity
for assessing the pathological substrates of MS, in par-
ticular demyelination and neuroaxonal loss, providing
better prognostic information [13, 40–42]. These include
magnetization transfer (MT) imaging and its quantitative
index MT ratio which has been proposed as a marker of
brain myelin content, also in the cerebral cortex; diffu-
sion tensor MRI tractography for axonal loss; and proton
MR spectroscopy that records signals from metabolites
as N-acetyl aspartate, a marker of neuroaxonal integrity,
or choline and lactate, biochemical correlates of inflam-
mation and demyelination. Additional insights into the
characteristics of MS lesions have been obtained from
iron-sensitive MRI sequences, especially at very high
field strengths (7.0 Tesla) where its accumulation shows
a close match to neurodegeneration. These quantitative
MR techniques by measuring the disease burden within
focal lesions and in the normal-appearing CNS instead
volume changes are contributing significantly to the un-
derstanding of the pathological mechanisms underlying
the irreversible accumulation of disability in PMS. How-
ever, and despite their potential, most of the new MR
techniques still require future research and validation.
Potential therapies
Oligodendrocytes and axons express neurotransmitter
receptors to glutamate so it may act as a potential exci-
totoxin under acute and chronic insults, and ultimately
contribute to neurodegeneration in PMS. Thus, numer-
ous studies conducted in cellular and animal models of
MS, as well as in post-mortem brain and in patients, in-
dicate that excitotoxicity mediated by Ca2+‐permeable
glutamate receptors contributes to oligodendrocyte death,
demyelination, and tissue damage in MS [43]. In particular,
experimental MS is alleviated by α‐amino‐3‐hydroxy‐5‐
methyl‐4‐isoxazolepropionate (AMPA) and kainate
receptor antagonists, but not N‐methyl‐d‐aspartate recep-
tor blockade, and combination with anti-inflammatory
agents expands neuroprotection even at advanced disease
stages [44]. Moreover, genome-wide association screening
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to brain volume loss in patients with high glutamate levels
[45]. In turn, glutamate levels are increased in the brain in
MS as a consequence of reduced expression of the glu-
tamate transporters (excitatory amino acid transporters 1
and 2) and upregulation of the cystine/glutamate antiporter
in the monocyte-macrophage-microglia lineage is associ-
ated with immune activation in both MS and experimental
autoimmune encephalomyelitis (EAE) [43, 46]. Like glu-
tamate, ATP, when in excess, is a potent endogenous toxin
that can directly kill oligodendrocytes via activation of puri-
nergic P2X7 receptors whose blockade during the chronic
phase of EAE attenuates the symptoms and tissue damage
[47]. Interestingly, P2X7 variants are associated with a
reduced or increased risk to suffer from MS [48, 49]. All
in all, these studies in MS animal models and in the dis-
ease proper offer new ideas to develop novel therapies
to treat PMS.
Recently, results of clinical trials have challenged the
long-held belief that pathogenesis of PMS is more neu-
rodegenerative than inflammatory, and distinct from
these aspects in RRMS. Indeed, ocrelizumab, a human-
ized monoclonal antibody targeting CD20 B cells, has
significant efficacy in both forms of MS reducing the re-
lapse rate in RRMS and delaying the risk of clinical dis-
ability progression in RRMS and, although modestly,
also for the first time in primary PMS [50]. Pivotal ocre-
lizumab trials [51, 52] had showed that mature B cells,
which express the antigen CD20 on their surface, played
a central role in the pathophysiology of RRMS traditionally
considered to be driven by T cells due to the observations
of activated T lymphocytes in MS plaques [2, 3, 6, 19].
This idea is now extended to PMS where lymphoid folli-
cles containing B cells are present in the meninges [32].
Although the mechanisms whereby anti-CD20 exerts its
beneficial effects are not well understood, there is evidence
that CD20 B cells, which represent a few percent of the
total B-cell pool, are involved in progressive aspects of MS
[53]. Moreover, clinical trials have shown that CD20 B-cell
depletion is effective without significant compromise of
the normal immune reactivity. Further stratification of dis-
ease subtypes will be needed for a better understanding of
the complex roles of B cells in MS [54–56]. Also, if the
presence of disease activity measured as T1 gadolinium-
enhancing lesions favours the response to ocrelizumab as
suggested by recent data [57]. However, the lack of bio-
markers predicting the level of activity and/or progression
in MS, namely active demyelination and neurodegenera-
tion, hinders the stratification of disease types [11, 18].
In this regard, further promising developments in PMS
therapies with targeted disease-modifying drugs may
contribute to better understanding the underlying mo-
lecular and cellular pathology of MS. Lastly, but not
least, global research collaboration will be needed toovercome the challenges of understanding and treating
efficiently PMS [23, 58].Conclusions
In MS, the progression of disease is the consequence of
a pathogenic cascade of events caused and/or related to
long-lasting accumulation of CNS damage which initi-
ated earlier, even when clinical symptoms were not
present. Chronic inflammation and neurodegeneration
are interlinked in MS from early stages of disease course
and there are multiple potential mechanisms that trigger
and sustain damage in PMS [59, 60]. Oxidative damage,
severe ion channel dysfunction, mitochondrial injury,
microglial activation without obvious disruption of the
BBB, and age related changes in CNS, are mechanisms
that also contribute to other neurodegenerative diseases.
Unlike in other neurodegenerative conditions, there is
no evidence of a primary trigger in MS for myelin and
oligodendrocytic injury, and it is unknown why usually it
has not a monophasic course from its beginning. Per-
haps the absence of remission in PMS is a sign of ex-
haustion of CNS compensatory mechanisms rather than
a change in the disease process. Moreover, there is no
imaging, pathological, or biomarker characteristics that
reliably distinguish between first episodes of MS and
progressive MS. Although the molecular and cellular
mechanisms driving the cyclic course and/or progression
of disease are incompletely understood, widespread and
diffuse loss of neurons and axons in the white and grey
matter with resultant atrophy has a key role in disability
progression in MS. In fact, subpial cortical demyelin-
ation appears to be exquisitely specific for MS, since it is
not present in any other inflammatory, neurodegenera-
tive or metabolic CNS disease. Despite the unknowns,
from a therapeutic point of view, a combination of im-
munomodulatory and neuroprotective strategies intro-
duced earlier in the development of disease appear to be
the most promising strategy to limit the progression of
MS. Also appropriate animal models, good biomarkers
and imaging measures remain indispensable to under-
stand the disease and test novel potential treatments.Abbreviations
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